Survey on effects of primary HPV screening and cytology practice in Europe
In 2018, the WHO called for a global incentive to eliminate cervical cancer as a public health issue. The Working Group concluded that both cytology and HPV nucleic acid testing are able to reduce the incidence and mortality of cervical cancer, with HPV testing leading to a larger reduction in cervical cancer incidence. The Working group underscored the need for adequate training and quality assurance in cytology-based screening (Bouvard et al, 2021)
The present survey is conducted as a project of the European Federation of Cytology Societies.
The primary goal is to map the current and planned cervical screening strategies in the different member countries.
Secondary end points are to measure the effects of primary HPV screening on cytology workload, diagnosis, and training.
The results of the survey will be published in a scientific journal and on the website of the EFCS.
We thank you for your participation in this survey.